Table 5.
Five most commonly prescribed first-line treatment regimens by histologic category.
| Histologic category and treatment | N (%) |
|---|---|
| Nonuterine leiomyosarcoma (n=144) | |
| Doxorubicin | 67 (46.5) |
| Doxorubicin + ifosfamidea | 24 (16.7) |
| Docetaxel + gemcitabine | 15 (10.4) |
| Ifosfamidea | 9 (6.3) |
| Dacarbazine + doxorubicin + ifosfamidea | 5 (3.5) |
|
| |
| Uterine leiomyosarcoma (n=85) | |
| Docetaxel + gemcitabine | 33 (38.8) |
| Doxorubicin + ifosfamidea | 15 (17.6) |
| Doxorubicin | 14 (16.5) |
| Trabectedin | 7 (8.2) |
| Carboplatin + paclitaxel | 2 (2.4) |
|
| |
| Fibroblastic/myofibroblastic sarcoma (n=78) | |
| Doxorubicin | 32 (41.0) |
| Doxorubicin + ifosfamidea | 13 (16.7) |
| Ifosfamidea | 6 (7.7) |
| Epirubicin + ifosfamidea | 6 (7.7) |
| Dacarbazine + ifosfamidea | 4 (5.1) |
|
| |
| Liposarcoma (n=105) | |
| Doxorubicin | 65 (61.9) |
| Doxorubicin + ifosfamidea | 15 (14.3) |
| Docetaxel + gemcitabine | 3 (2.9) |
| Docetaxel | 3 (2.9) |
| Trabectedin | 3 (2.9) |
|
| |
| Vascular sarcoma (n=79) | |
| Paclitaxel | 28 (35.4) |
| Doxorubicin | 18 (22.8) |
| Doxorubicin + ifosfamidea | 7 (8.9) |
| Ifosfamidea | 4 (5.1) |
| Docetaxel + gemcitabine | 3 (3.8) |
|
| |
| Rhabdomyosarcoma (n=86) | |
| Doxorubicin | 34 (39.5) |
| Doxorubicin + ifosfamidea | 19 (22.1) |
| Ifosfamidea | 5 (5.8) |
| Pazopanib | 5 (5.8) |
| Docetaxel + gemcitabine | 3 (3.5) |
|
| |
| Synovial sarcoma (n=47) | |
| Doxorubicin | 23 (48.9) |
| Doxorubicin + ifosfamidea | 7 (14.9) |
| Ifosfamidea | 4 (8.5) |
| Docetaxel + gemcitabine | 3 (6.4) |
| Paclitaxel | 3 (6.4) |
|
| |
| Others/NOS (n=183) | |
| Doxorubicin | 77 (42.1) |
| Doxorubicin + ifosfamidea | 53 (29.0) |
| Docetaxel + gemcitabine | 9 (4.9) |
| Epirubicin + ifosfamidea | 7 (3.8) |
| Dacarbazine + doxorubicin + ifosfamidea | 4 (2.2) |
NOS: not otherwise specified; Denominators for the percentages are patients who received one of the five most commonly prescribed first-line regimens within each histologic category; amesna was always coadministered with ifosfamide.